Tenofovir regimen compared with Combivir.
D000225:Adenine / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005060:Europe; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000175:diagnosis* / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D020714:Maximum Tolerated Dose; D063065:Organophosphonates / Q000008:administration & dosage* / Q000009:adverse effects; D018570:Risk Assessment; D012720:Severity of Illness Index; D016037:Single-Blind Method; D000068698:Tenofovir; D016896:Treatment Outcome; D014481:United States; D019562:Viral Load; D015215:Zidovudine / Q000008:administration & dosage* / Q000009:adverse effects
D004338:Drug Combinations; D063065:Organophosphonates; C109078:lamivudine, zidovudine drug combination; D019259:Lamivudine; D015215:Zidovudine; D000068698:Tenofovir; D000225:Adenine